These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
552 related articles for article (PubMed ID: 24172896)
1. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Shingai M; Nishimura Y; Klein F; Mouquet H; Donau OK; Plishka R; Buckler-White A; Seaman M; Piatak M; Lifson JD; Dimitrov DS; Nussenzweig MC; Martin MA Nature; 2013 Nov; 503(7475):277-80. PubMed ID: 24172896 [TBL] [Abstract][Full Text] [Related]
2. Early antibody therapy can induce long-lasting immunity to SHIV. Nishimura Y; Gautam R; Chun TW; Sadjadpour R; Foulds KE; Shingai M; Klein F; Gazumyan A; Golijanin J; Donaldson M; Donau OK; Plishka RJ; Buckler-White A; Seaman MS; Lifson JD; Koup RA; Fauci AS; Nussenzweig MC; Martin MA Nature; 2017 Mar; 543(7646):559-563. PubMed ID: 28289286 [TBL] [Abstract][Full Text] [Related]
3. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Barouch DH; Whitney JB; Moldt B; Klein F; Oliveira TY; Liu J; Stephenson KE; Chang HW; Shekhar K; Gupta S; Nkolola JP; Seaman MS; Smith KM; Borducchi EN; Cabral C; Smith JY; Blackmore S; Sanisetty S; Perry JR; Beck M; Lewis MG; Rinaldi W; Chakraborty AK; Poignard P; Nussenzweig MC; Burton DR Nature; 2013 Nov; 503(7475):224-8. PubMed ID: 24172905 [TBL] [Abstract][Full Text] [Related]
5. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300 [TBL] [Abstract][Full Text] [Related]
6. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171 [TBL] [Abstract][Full Text] [Related]
7. Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Julg B; Pegu A; Abbink P; Liu J; Brinkman A; Molloy K; Mojta S; Chandrashekar A; Callow K; Wang K; Chen X; Schmidt SD; Huang J; Koup RA; Seaman MS; Keele BF; Mascola JR; Connors M; Barouch DH J Virol; 2017 Aug; 91(16):. PubMed ID: 28539448 [TBL] [Abstract][Full Text] [Related]
8. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981 [TBL] [Abstract][Full Text] [Related]
9. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869 [TBL] [Abstract][Full Text] [Related]
10. V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques. Ho SH; Shek L; Gettie A; Blanchard J; Cheng-Mayer C J Virol; 2005 Oct; 79(19):12296-303. PubMed ID: 16160156 [TBL] [Abstract][Full Text] [Related]
11. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322 [TBL] [Abstract][Full Text] [Related]
12. Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIV Jia M; Lu H; Kong XP; Cheng-Mayer C; Wu X Viruses; 2018 May; 10(5):. PubMed ID: 29772652 [TBL] [Abstract][Full Text] [Related]
14. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. Crawford JM; Earl PL; Moss B; Reimann KA; Wyand MS; Manson KH; Bilska M; Zhou JT; Pauza CD; Parren PW; Burton DR; Sodroski JG; Letvin NL; Montefiori DC J Virol; 1999 Dec; 73(12):10199-207. PubMed ID: 10559336 [TBL] [Abstract][Full Text] [Related]
15. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095 [TBL] [Abstract][Full Text] [Related]
16. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. Laird ME; Igarashi T; Martin MA; Desrosiers RC J Virol; 2008 Nov; 82(22):11054-65. PubMed ID: 18768967 [TBL] [Abstract][Full Text] [Related]
17. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411 [TBL] [Abstract][Full Text] [Related]
18. Immune Responses and Viral Persistence in Simian/Human Immunodeficiency Virus SHIV.C.CH848-Infected Rhesus Macaques. Ziani W; Bauer A; Lu H; Wang X; Wu X; Bar KJ; Li H; Liu D; Shaw GM; Veazey RS; Xu H J Virol; 2021 Apr; 95(9):. PubMed ID: 33568508 [TBL] [Abstract][Full Text] [Related]
19. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges. Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914 [TBL] [Abstract][Full Text] [Related]
20. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques. Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]